LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Average Recommendation of “Hold” by Brokerages

Shares of LAVA Therapeutics N.V. (NASDAQ:LVTX) have received an average recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $2.6850.

A number of equities analysts have issued reports on the stock. Jefferies Financial Group cut shares of LAVA Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $3.00 to $1.50 in a report on Tuesday, August 5th. HC Wainwright cut their target price on shares of LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating on the stock in a report on Tuesday, August 5th.

Insider Transactions at LAVA Therapeutics

In other news, major shareholder Versant Venture Capital Vi, L. sold 2,370,533 shares of LAVA Therapeutics stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $1.40, for a total transaction of $3,318,746.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 4,587,837 shares of company stock valued at $6,564,826 over the last quarter. Company insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Lepercq De Neuflize Asset Management LLC acquired a new position in LAVA Therapeutics in the first quarter worth approximately $29,000. XTX Topco Ltd acquired a new stake in shares of LAVA Therapeutics during the 1st quarter valued at $31,000. Rangeley Capital LLC acquired a new stake in shares of LAVA Therapeutics during the 2nd quarter valued at $36,000. BNP Paribas Financial Markets acquired a new stake in shares of LAVA Therapeutics in the 4th quarter valued at $40,000. Finally, BML Capital Management LLC acquired a new stake in shares of LAVA Therapeutics in the 1st quarter valued at $2,490,000.

LAVA Therapeutics Stock Performance

NASDAQ:LVTX opened at $1.58 on Wednesday. The company has a market capitalization of $41.57 million, a price-to-earnings ratio of -1.50 and a beta of 0.50. LAVA Therapeutics has a one year low of $0.85 and a one year high of $2.09. The stock has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $1.36.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). On average, equities research analysts forecast that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.